Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > Mitchell continues buying........

<< Previous

Bullboard Posts

Next >>

Comment by Maxmoeon Feb 21, 2019 8:10am

44 Views

Post# 29392445

RE:Mitchell continues buying........

He is close to being maxed out with osc rules for partially diluted staying under 20%. Assuming 75 million outstanding partly diluted ( include his warrants only) his max would be 15 million. I’m rounding. He now owns, partly diluted, 13.2 million. So far, no sign of insider selling into his bid. I was wondering if evenergy would be exiting Canada under direction from Beijing. Ink research shows no activity since January of 2018 for evenergy but I’m not sure of the frequency requirements of their reporting.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments